Science Explorer Back to mapMap
Discussion
Institution · Helios Hospital Berlin-Buch

Most cited papers from Helios Hospital Berlin-Buch

Helios Hospital Berlin-Buch

What are the most cited papers from Helios Hospital Berlin-Buch?

The most cited paper from Helios Hospital Berlin-Buch is "Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis" (Patricia Cortazar et al., 2014), with 4,858 citations. Next come "Pembrolizumab for Early Triple-Negative Breast Cancer" (3,298) and "Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer" (2,689).

Showing 50 of 60 papers. Every paper with more than 430 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Patricia Cortazar et al. · The Lancet Open access 13 Feb 2014 4,858
2 Pembrolizumab for Early Triple-Negative Breast Cancer Peter Schmid et al. · New England Journal of Medicine Open access 26 Feb 2020 3,298
3 Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer Gϋnter von Minckwitz et al. · New England Journal of Medicine Open access 5 Dec 2018 2,689
4 Cardiovascular Magnetic Resonance in Myocarditis: A JACC White Paper Matthias G. Friedrich, Udo P Sechtem, Jeanette Schulz‐Menger et al. · Journal of the American College of Cardiology Open access Apr 2009 2,526
5 Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy Carsten Denkert et al. · The Lancet Oncology 8 Dec 2017 2,205
6 Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial Jaap Verweij, Paolo Giovanni Casali, John Raymond Zalcberg et al. · The Lancet Sep 2004 1,676
7 Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up Paolo Giovanni Casali et al. · Annals of Oncology Open access 28 Mar 2018 1,636
8 Association analysis identifies 65 new breast cancer risk loci Kyriaki Michailidou et al. · Nature Open access362 authors 20 Oct 2017 1,602
9 Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) Board of Trustees Task Force on Standardized Post Processing Jeanette Schulz‐Menger, David A. Bluemke, Jens Bremerich et al. · Journal of Cardiovascular Magnetic Resonance Open access 2013 1,528
10 Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study Thorsten Kuehn, Ingo Bauerfeind, Tanja Natascha Fehm et al. · The Lancet Oncology 14 May 2013 1,498
11 Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells Markus Kleinewietfeld, Arndt Manzel, Jens Marc Titze et al. · Nature Open access 5 Mar 2013 1,405
12 Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes Nasim Mavaddat et al. · The American Journal of Human Genetics Open access269 authors 13 Dec 2018 1,213
13 Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ Alessandro Gronchi et al. · Annals of Oncology Open access 22 Jul 2021 1,057
14 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial David Cameron, Martine J Piccart, Richard D. Gelber et al. · The Lancet Open access 16 Feb 2017 1,052
15 Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial Gϋnter von Minckwitz et al. · The Lancet Oncology 30 Apr 2014 1,048
16 Standardized image interpretation and post-processing in cardiovascular magnetic resonance - 2020 update Jeanette Schulz‐Menger, David A. Bluemke, Jens Bremerich et al. · Journal of Cardiovascular Magnetic Resonance Open access 2020 1,027
17 A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma Eva Hoster, Martin H. Dreyling, Wolfram Klapper et al. · Blood 25 Oct 2007 986
18 One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor Heikki Joensuu et al. · JAMA 27 Mar 2012 982
19 Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C–dependent buffering mechanism Agnes Machnik et al. · Nature Medicine May 2009 971
20 Common genetic variants influence human subcortical brain structures The Alzheimer’s Disease Neuroimaging Initiative et al. · Nature Open access291 authors 20 Jan 2015 934
21 Clinical Characteristics and Cardiovascular Magnetic Resonance Findings in Stress (Takotsubo) Cardiomyopathy Ingo Eitel, Florian von Knobelsdorff‐Brenkenhoff, Peter Bernhardt et al. · JAMA 19 Jul 2011 815
22 Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial Manali Kamdar et al. · The Lancet Open access Jun 2022 799
23 Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study Valentino Conter et al. · Blood Open access 12 Feb 2010 795
24 Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial Sibylle Loibl, Joyce O’Shaughnessy, Michael Untch et al. · The Lancet Oncology 28 Feb 2018 781
25 Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up Paolo Giovanni Casali et al. · Annals of Oncology Open access 28 Mar 2018 759
26 Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort Sigbjørn Smeland et al. · European Journal of Cancer Open access 27 Jan 2019 748
27 Color Duplex Ultrasonography in the Diagnosis of Temporal Arteritis Wolfgang Schmidt, Helga E. Kraft, Klaus Vorpahl et al. · New England Journal of Medicine Open access 6 Nov 1997 719
28 A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study S. Loibl et al. · Annals of Oncology Open access 7 May 2019 714
29 Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol Geeta Gulati, Siri Lagethon Heck, Anne Hansen Ree et al. · European Heart Journal Open access 21 Feb 2016 696
30 Activation of the Peripheral Endocannabinoid System in Human Obesity Stefan Engeli, Jana Böhnke, Mareike Feldpausch et al. · Diabetes Open access Oct 2005 696
31 Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up Paolo Giovanni Casali et al. · Annals of Oncology Open access 2 Aug 2018 655
32 Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Peter C Thuss-Patience, Albrecht Kretzschmar, Dmitry Bichev et al. · European Journal of Cancer 13 Jul 2011 617
33 Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95 Anja Möricke et al. · Blood Open access 19 Feb 2008 616
34 Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial Luca Gianni et al. · The Lancet Oncology 26 Feb 2011 614
35 Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up Paolo Giovanni Casali et al. · Annals of Oncology Open access 21 Sep 2021 608
36 Lower tidal volume strategy (≈3 ml/kg) combined with extracorporeal CO2 removal versus ‘conventional’ protective ventilation (6 ml/kg) in severe ARDS Thomas Bein, Steffen Weber‐Carstens, Anton Goldmann et al. · Intensive Care Medicine Open access 9 Jan 2013 604
37 Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials Julia Bohlius et al. · The Lancet Review May 2009 598
38 Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study Henryk Barthel, Hermann‐Josef Gertz, Stefan H. J. Dresel et al. · The Lancet Neurology 11 Apr 2011 596
39 Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial Penella J. Woll, Peter Reichardt, Axel Le Cesne et al. · The Lancet Oncology 3 Sep 2012 596
40 Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study Sant P. Chawla, Robert Mikael Henshaw, Leanne L. Seeger et al. · The Lancet Oncology 15 Jul 2013 589
41 Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses Haoyu Zhang et al. · Nature Genetics Open access276 authors 18 May 2020 587
42 Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials Carsten Denkert et al. · The Lancet Oncology 9 Jul 2021 581
43 Anticoagulant Reversal, Blood Pressure Levels, and Anticoagulant Resumption in Patients With Anticoagulation-Related Intracerebral Hemorrhage Joji B. Kuramatsu et al. · JAMA 24 Feb 2015 568
44 Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial Neyssa M. Marina et al. · The Lancet Oncology Open access 31 Aug 2016 559
45 Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer Peter Schmid et al. · New England Journal of Medicine Open access 15 Sep 2024 544
46 Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study Eric Van Cutsem, Fernando Rivera, Scott R. Berry et al. · Annals of Oncology Open access May 2009 536
47 Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000 Anja Möricke et al. · Leukemia 10 Dec 2009 527
48 Increased Vascular Smooth Muscle Contractility in TRPC6−/− Mice Alexander M. Dietrich, Michael Mederos y Schnitzler, Maik Gollasch et al. · Molecular and Cellular Biology Open access 29 Jul 2005 516
49 The Salvaged Area at Risk in Reperfused Acute Myocardial Infarction as Visualized by Cardiovascular Magnetic Resonance Matthias G. Friedrich, Hassan Abdel‐Aty, Andrew J. Taylor et al. · Journal of the American College of Cardiology Open access Apr 2008 513
50 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch et al. · The Lancet 17 Jul 2013 504

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.